Efficacy of Parenteral Cefotaxime Versus Combination of Piperacillin & Tazobactam as Empiric First Line Therapy in the Treatment of Spontaneous Bacterial Peritonitis
Keywords:
Ascitic fluid analysis, Cefotaxime, Cirrhosis, Neutrophil count, Piperacillin-Tazobactam, Spontaneous bacterial peritonitis(SBP)Abstract
Introduction: Cefotaxime is the empiric antibiotic of choice for spontaneous bacterial peritonitis (SBP). However, rising gram-positive pathogen rates have prompted consideration of piperacillin-tazobactam as an alternative. This study compares their efficacy in treating SBP among cirrhotic patients.
Methods: Thirty hospitalized cirrhotic patients diagnosed with SBP (ascitic fluid neutrophils > 250/mm3) were randomized into two groups: 15 received cefotaxime (2g IV twice daily), and 15 received Piperacilin-Tazobactam (4.5 g IV every eight hours), both for five days. More than 25% reduction in neutrophil count after 48 hours defined treatment response.
Results: The response rate was 60% (9/15) in the cefotaxime group vs. 93.3% (14/15) in the piperacillin-tazobactam group (p=0.084). Among patients with prior SBP on quinolone prophylaxis, 75% receiving cefotaxime failed to respond, while 80% receiving Piperacillin-Tazobactam responded.
Conclusion: Piperacillin/Tazobactam is as effective as Cefotaxime and may be superior in patients with prior SBP episodes on prophylaxis. These common clinical scenarios suggest Piperacillin-Tazobactam could be a more suitable empiric first line therapy for SBP in cirrhotic patients.
Downloads
Published
How to Cite
Issue
Section
License
Copyright (c) 2025 The Author(s)
This work is licensed under a Creative Commons Attribution 4.0 International License.
This license enables reusers to distribute, remix, adapt, and build upon the material in any medium or format, so long as attribution is given to the creator. The license allows for commercial use.
